Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.

Journal of diabetes investigation - 1 Sept 2016

Zeng Wotan, Guo Yali, Chen Peixian, Liu Zhike, Chen Dafang, Han Chunji

Abstract excerpt

AIMS/INTRODUCTION: The objective of the present study was to investigate the effects of CYP2C9*3 polymorphisms on the therapeutic response to gliclazide in type 2 diabetes patients. MATERIALS AND METHODS: A total of 746 incident type 2 diabetes patients were included in this study. After enrolment, patients went on 4-week gliclazide monotherapy. Fasting plasma glucose was measured before and after treatment....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to China
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Genotype

Share to Hypoglycemic Agents

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 27181593
DOI: 10.1111/jdi.12486
PMCID: PMC5009140

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.PMID 27181593Read ↗

Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.Semantic proximity Read ↗

CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide.Semantic proximity Read ↗

CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.Semantic proximity Read ↗

Pharmacogenetic studies update in type 2 diabetes mellitusSemantic proximity Read ↗

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Semantic proximity Read ↗

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicineSemantic proximity Read ↗

Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of Oral Antidiabetic DrugsSemantic proximity Read ↗

Clinical Study on the Relationship between the SNP rs8192675 (C/C) Site of SLC2A2 Gene and the Hypoglycemic Effect of Metformin in Type 2 Diabetes.Semantic proximity Read ↗

Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.Semantic proximity Read ↗

Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.Semantic proximity Read ↗

Pharmacogenetics of Type 2 Diabetes—Progress and ProspectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.